The global demand for Insulin Glargine Market is presumed to reach the valuation of nearly USD XX MN by 2028 from USD XX MN in 2021 with a CAGR of XX% during the period of 2022-2028. Whereas with regards to volume, the market was calculated XX KT in 2021 and foreseen to touch XX KT by 2028 with a CAGR of XX% during 2020-2026.
Insulin glargine is a man-made version of human insulin used to treat type 1 diabetes and type 2 diabetes. It works by replacing the insulin that is usually produced by the body, also helps boost energy, and stops the liver from producing more sugar. It comes as a solution to inject subcutaneously. Insulin glargine therapy may also decrease the chances of having a heart attack, stroke, and other diabetes-associated complications such as nerve damage, eye problems, kidney failure, including changes or loss of vision, or gum disease.v
The rising burden of diabetes drives the global insulin glargine market. As per Diabetes Research and Clinical Practice, the global diabetes prevalence in 2019 is estimated to be 463 million people, rising to 578 million by 2030 and 700 million by 2045. The prevalence is higher in urban than in rural areas and high-income than in low-income countries. Further advances in insulin delivery technology will stimulate the growth of the market. Growing measures brought out for fast and convenient medical reimbursement policies will amplify treatment for diabetes and hence the demand for insulin glargine. However, lack of knowledge about diabetes treatment in rural areas will hinder the market’s growth.
The report covers Porter’s Five Forces Model, Market Attractiveness Analysis and Value Chain analysis. These tools help to get a clear picture of the industry’s structure and evaluate the competition attractiveness at a global level.
Additionally, these tools also give inclusive assessment of each application/product segment in the global market of insulin glargine.
The entire Insulin Glargine market has been sub-categorized into type, application, distribution channel. The report provides an analysis of these subsets with respect to the geographical segmentation. This research study will keep marketer informed and helps to identify the target demographics for a product or service.
- Single Dose Vial
- Pre-filled Syringe
By Distribution Channel
- Treat type2 diabetes
- Treat type1 diabetes
- Hospitals Pharmacy
- Retail Pharmacy
- Online Sales
This section covers regional segmentation which accentuates on current and future demand for insulin glargine market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand for individual application segment across all the prominent regions.
Global Insulin Glargine Market Share by Region (Representative Graph)
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the insulin glargine market include Sanofi-Aventis, Ganlee. Biocon. This section includes a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
This market research report has been produced by gathering information on the basis of primary and secondary research. Secondary research has been done by using various sources which include (but not limited to) Company Websites, Paid Data Sources, Technical Journals, Financial Reports, SEC Filings, and other different industry publications.
If specific information is required which is not currently within the scope of the report, it can be provided as a part of customization.